Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRA023 for systemic sclerosis-associated interstitial lung disease
MOH_2022-05-19_010810Phase 3Not yet recruiting
- Sponsor
- Prometheus Biosciences
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing PRA023 with Placebo (2 arms). Primary endpoints: Annualized rate of change from baseline in forced vital capacity and Safety and tolerability of PRA023. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tulisokibart
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2022-05-19_010810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-19_010810.